ArticleThe Journal of experimental medicine2018
Shared cancer neoantigens: Making private matters public.
Article in The Journal of experimental medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 59 citations in OpenAlex.
- Bright side of the dark genome: antigens for next-gen cancer vaccines.Journal for immunotherapy of cancer · 2026Review
- Identification of public neoantigens with broad HLA class I coverage as candidates for off-the-shelf cancer vaccine development in colorectal cancer.Frontiers in immunology · 2026Article
- Non-canonical and induced neoantigens as emerging sources of cancer-specific immunotherapy targets.Frontiers in immunology · 2026Review
- Isolation of mitochondrial mutation-specific T cell receptors.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- A structure-guided approach to predict MHC-I restriction of T cell receptors for public antigens.Structure (London, England : 1993) · 2025Article
- Shared neoantigens for cancer immunotherapy.Molecular therapy. Oncology · 2025Review
- Potential shared neoantigens from pan-cancer transcript isoforms.Scientific reports · 2025Article
- Multi-disciplinary approaches paving the way for clinically effective peptide vaccines for cancer.NPJ vaccines · 2025Review
- Lung cancer vaccine strategies: exploring the spectrum from traditional to RNA-based platforms.Frontiers in bioengineering and biotechnology · 2025Review
- Neoantigen immunotherapy: a novel treatment for bladder cancer.Exploration of targeted anti-tumor therapy · 2025Review
- Systematic discovery of neoepitope-HLA pairs for neoantigens shared among patients and tumor types.Nature biotechnology · 2024Article
- Public neoantigens in breast cancer immunotherapy (Review).International journal of molecular medicine · 2024Review
- VACCIMEL, an allogeneic melanoma vaccine, efficiently triggers T cell immune responses against neoantigens and alloantigens, as well as against tumor-associated antigens.Frontiers in immunology · 2024Article
- Neoantigen cancer vaccines: a new star on the horizon.Cancer biology & medicine · 2023Review
- T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome.Nature reviews. Drug discovery · 2023Review
- Personalized Cancer Vaccines Go Viral: Viral Vectors in the Era of Personalized Immunotherapy of Cancer.International journal of molecular sciences · 2023Review
- Worth a Pound of Cure? Emerging Strategies and Challenges in Cancer Immunoprevention.Cancer prevention research (Philadelphia, Pa.) · 2023Review
- Whole tumour cell-based vaccines: tuning the instruments to orchestrate an optimal antitumour immune response.British journal of cancer · 2023Review
- Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th-December 1st, 2022).Journal of translational medicine · 2023Article
- Neoantigens: promising targets for cancer therapy.Signal transduction and targeted therapy · 2023Review
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this issue of JEM, Chheda et al. (https://doi.org/10.1084/jem.20171046) report that a conserved hotspot mutation associated with an aggressive form of brain cancer generates an immunogenic T cell epitope restricted by a common HLA subtype, thereby creating a "public" neoantigen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.